Company profile: ViOptix
1.1 - Company Overview
Company description
- Provider of innovative proprietary tissue oximetry solutions measuring oxygen saturation levels in tissues, including near infrared generators and single-use disposable sensors, plus systems: T.Ox for real-time, non-invasive monitoring following surgery; T.Ox Remote for Wi-Fi access to oxygenation data; and Intra.Ox for handheld perfusion assessments.
Products and services
- Intra.Ox: A handheld device that delivers non-invasive, real-time estimation of tissue oxygen saturation during perfusion assessments using near-infrared
- T.Ox: A system that delivers real-time, non-invasive monitoring of oxygen saturation in targeted tissues following surgery using near-infrared
- T.Ox Remote: A Wi‑Fi-enabled platform that offers clinicians remote access to tissue oxygenation data in real time, enabling rapid intervention.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ViOptix
Retension Pharmaceuticals
HQ: United States
Website
- Description: Provider of healthcare solutions focused on RTN-001, a tissue-targeted PDE5 inhibitor designed to treat hypertension by enhancing nitric oxide action in the central pulmonary vasculature, promoting vasodilation and blood pressure control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Retension Pharmaceuticals company profile →
Essential Medical
HQ: United States
Website
- Description: Provider of femoral artery closure devices to seal femoral punctures following vascular access medical procedures requiring a cardiac catheterization. The company has developed two devices, including MANTA, designed to close large-bore punctures (10–24F) after procedures such as transcatheter aortic valve replacement (TAVR) and abdominal aortic aneurysm.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Essential Medical company profile →
Cardurion Pharmaceuticals
HQ: United States
Website
- Description: Provider of cardiovascular therapeutics and research services, developing a PDE9 inhibitor for HFrEF and HFpEF to enhance existing therapy; a CaMKII inhibitor for CPVT, heart failure, and atrial fibrillation; and conducting clinical trials, plus medicinal chemistry, computational molecular modeling, and genetic engineering support for cardiovascular research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cardurion Pharmaceuticals company profile →
Corvidia Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage research, development, and commercialization of transformative therapies for cardio-renal diseases, currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corvidia Therapeutics company profile →
Corvia Medical
HQ: United States
Website
- Description: Provider of transcatheter structural heart devices for heart failure, including the Corvia Atrial Shunt (InterAtrial Shunt Device) designed to treat diastolic heart failure/HFpEF by reducing pressures in the heart and lungs, supported by clinical evidence and the RESPONDER-HF clinical study assessing efficacy in patients with EF ≥40%.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corvia Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ViOptix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ViOptix
2.2 - Growth funds investing in similar companies to ViOptix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ViOptix
4.2 - Public trading comparable groups for ViOptix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →